Smith and Nephew

Rank: 22
2016 Rank25
R&D Spend:$230,000,000
Fiscal year ending:12-31-16
Click here to see all 100

Smith and Nephew, a perennial subject of takeover gossip, suffered another year of rumors around a possible buyout by Stryker. Instead, Smith and Nephew went on the MandA trail itself, buying Russia’s DeOst group for an undisclosed amount and the U.S. unicompartmental High Flex knee assets Zimmer was forced to divest to mollify U.S. anti-trust regulators on its $13.34 billion Biomet merger. (Biomet was forced to deal its Discovery elbow, Cobalt bone cement, Optivac cement mixing accessories and SoftPac pouch to DJO global.) Smith and Nephew also ventured into the generic sales arewith its Syncera offering, a "no-frills" repless model for its orthopedic implants.

Smith & Nephew divests Gynaecology business for $350 million and announces associated $300 million share buy-back program. Smith & Nephew unveils our first 3D-printed titanium hip implant. Smith & Nephew completes first BST-CarGel® cartilage repair procedure following acquisition. Colombian surgeon performs first total knee replacement using Smith & Nephew’s VISIONAIRE™ Cutting Guides in Latin America.

Big 100 Mini Logo Key Personnel: Olivier Bohuon, CEO; Graham Baker, CFO; Rodrigo Bianchi, president, international; Brad Cannon, president, Europe & Canada; Elga Lohler, chief HR officer; Catheryn O'Rourke, chief legal officer; Vasant Padmanabhan, president, R&D; Cyrille Petit, chief corporate development officer & president, global business services; Matthew Stober, president, global operations; Glenn Warner, president, U.S.;

London, London